Onalespib

Drug Overview

Onalespib (also known by its developmental code AT13387) is an investigational, small-molecule, non-geldanamycin inhibitor of Heat Shock Protein 90 (HSP90). HSP90 is a “chaperone” protein that plays a critical role in helping other proteins (known as “client proteins”) fold correctly, stay stable, and function within the cell.

In the clinical landscape of March 2026, onalespib is recognized as a potent “multi-target” therapy. Because many of the proteins that drive cancer—such as mutated EGFR, BRAF, and AKT—rely on HSP90 to survive, inhibiting this single chaperone can lead to the simultaneous degradation of multiple oncogenic pathways. This makes onalespib particularly valuable in treating “addicted” tumors that have developed resistance to single-target drugs (like Iressa or Zelboraf). By “crippling” the cellular machinery that stabilizes these mutant proteins, onalespib forces the cancer cell into a state of metabolic stress and eventual death.

• Generic Name: Onalespib.
• Code Name: AT13387.
• Drug Class: HSP90 Inhibitor; Molecular Chaperone Inhibitor.
• Mechanism: Competitive inhibition of the ATPase activity of HSP90, leading to the degradation of client oncoproteins.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, onalespib is not FDA-approved. It has been evaluated in numerous Phase 1 and Phase 2 trials for solid tumors and is currently a subject of research in combination with other targeted therapies.

What Is It and How Does It Work? (Mechanism of Action)

Onalespib works by disrupting the “quality control” system of the cancer cell.

1. The Role of HSP90

Under normal conditions, HSP90 helps proteins fold into their active 3D shapes. In cancer, many mutated proteins are inherently unstable. These “client proteins” (including HER2, BCR-ABL, c-Met, and V640E BRAF) become completely dependent on HSP90 to keep them from “unraveling” and being destroyed by the cell.

2. Competitive ATP Inhibition

Onalespib binds with high affinity to the ATP-binding pocket located in the N-terminal domain of the HSP90 protein.

• Blocking the Engine: By preventing ATP from binding, onalespib stops the “chaperone cycle” in its tracks.
• Misfolding: Without the help of HSP90, the client oncoproteins cannot maintain their shape and become “misfolded.”

3. Proteasomal Degradation

Once a protein is misfolded, the cell identifies it as “trash.”

• Ubiquitination: The misfolded client proteins are “tagged” with a molecule called ubiquitin.
• The Shredder: These tagged proteins are sent to the proteasome (the cell’s protein shredder), where they are broken down into harmless amino acids. By destroying the very proteins the cancer needs to grow, onalespib effectively shuts down multiple growth signals at once.

Clinical Indications and Research Status (2026)

Because HSP90 is universal, onalespib has been studied across a wide variety of “protein-heavy” cancers:

• Non-Small Cell Lung Cancer (NSCLC): Specifically for patients with EGFR mutations or ALK rearrangements who have developed resistance to first-line TKIs.
• Metastatic Melanoma: Studied in combination with vemurafenib or dabrafenib to prevent the “bypass signaling” that often leads to BRAF-inhibitor resistance.
• Gastrointestinal Stromal Tumors (GIST): Evaluated for patients who have failed imatinib and sunitinib.
• Advanced Solid Tumors: Investigated in combination with paclitaxel or docetaxel to see if HSP90 inhibition can sensitize tumors to traditional chemotherapy.

Dosage and Administration Protocols

As an investigational agent, onalespib dosing is strictly managed within clinical trial protocols (such as the AT13387-05 study).

Clinical Efficacy and Research Results

As of early 2026, results from Phase 1/2 trials have provided significant biological proof-of-concept:

• Durable Responses: In patients with ALK-positive lung cancer, onalespib has shown the ability to induce tumor shrinkage even after the cancer has progressed on crizotinib.
• Biomarker Depletion: Clinical biopsies have confirmed that onalespib successfully reduces the levels of “client proteins” like AKT and EGFR within the actual tumor tissue of patients.
• Synergy in Melanoma: Trials presented in late 2025 showed that adding onalespib to BRAF/MEK inhibitors delayed the onset of resistance by an average of 4 months compared to the inhibitors alone.

Safety Profile and Side Effects

The side effects of onalespib are generally related to its “off-target” effects on healthy cells that also utilize HSP90.

1. Gastrointestinal Issues

The most common side effect observed in clinical trials.

• Symptoms: Diarrhea (reported in over 70% of patients), nausea, and vomiting.
• Management: Usually managed with standard anti-diarrheals (like loperamide) and anti-emetics.

2. Ocular (Visual) Disturbances

A unique side effect of many HSP90 inhibitors.

• Symptoms: Flashing lights, blurred vision, or “halos” around objects.
• Cause: HSP90 is critical for the health of the retina. These symptoms are almost always temporary and resolve when the drug is stopped.

3. Common Side Effects (>25%):

• Fatigue: General systemic tiredness.
• Elevated Liver Enzymes: Transient increases in AST/ALT, requiring regular monitoring.
• Anorexia: Loss of appetite and subsequent weight loss.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, onalespib is being used to study “Proteostasis.” Researchers are investigating how “chaperone stress” affects the survival of Leukemia Stem Cells and whether HSP90 inhibition can be used to “flush out” dormant cancer cells that hide from chemotherapy. In 2026, there is also intense focus on “Onalespib-Immunotherapy Combinations.” Scientists are exploring if destroying oncogenic proteins with onalespib releases “neoantigens” that make the tumor more visible to the immune system, potentially making checkpoint inhibitors (like pembrolizumab) work more effectively.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Ocular Baseline: A baseline eye exam is often recommended to monitor for any visual changes during treatment.
• Baseline Blood Work: Comprehensive CBC and metabolic panel (especially liver function).

“Do’s and Don’ts” List:

• DO keep a “diarrhea diary” and have anti-diarrheal medication ready at home; managing the gut side effects is the key to staying on the treatment.
• DO report any “curtain-like” vision or severe flashes of light to your oncology team immediately.
• DON’T drive at night if you notice any changes in your vision or sensitivity to light after your infusion.
• DON’T assume that “more is better”; the dose of onalespib is carefully calculated to balance protein destruction with the health of your liver and eyes.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Onalespib (AT13387) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.